Cerecor Inc Closes on Initial Tranche of US$32M Series B Financing

Baltimore, MD, July 21, 2014 — Cerecor Inc, a clinical stage biopharmaceutical company developing innovative treatments to make a difference in the lives of patients suffering from nervous system disorders, today announced the closing of the first tranche of a $32M Series B financing. The investment round was led by New Enterprise Associates (NEA), Apple Tree Partners (ATP) and MPM Capital. Proceeds from the round will support the development of Cerecor’s lead product candidate CERC-301, a first-in-class, oral, selective NR2B inhibitor in Phase 2 development as a once-a-day adjunctive therapy for severe MDD (major depressive disorder) with a rapid onset of action, and its catechol-O-methyltransferase (COMT) inhibitor platform for various conditions characterized by impairment of executive function and working memory.

This entry was posted in Recent Development News: Q3 – 2014. Bookmark the permalink.